Parent-determined oral montelukast therapy for preschool wheeze with stratification for arachidonate-5-lipoxygenase (ALOX5) promoter genotype. - Wheeze And Intermittent Treatment; WAIT

Queen Mary University London0 个研究点目标入组 1,346 人开始时间: 2010年3月17日最近更新: 2019年6月30日

适应症

试验速览

暂无简介。

•age = 10 months and = 5 years on the day of the first dose of IMP.
•two or more attacks of parent-reported wheeze,
•at least one attack with wheeze validated by a clinician
•the most recent attack within the last 3 months.
•contactable by telephone and able to attend one face-to-face review for issue of IMP
•parent or guardian able to give written informed consent for their child participate in the study.
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

••any other chronic respiratory condition diagnosed by a clinician including structural airway abnormality (e.g. floppy larynx) and cystic fibrosis
•any chronic condition that increases vulnerability to respiratory tract infection such as severe developmental delay with feeding difficulty
•history of neonatal chronic lung disease
•current continuous oral montelukast therapy
•in a trial using an IMP within the previous 3 months prior to recruitment.

发起方